Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study

Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer. The biotech on Tuesday shared Phase 2